ArticleChemical science2026
Site-specific post-translational modification detection by polar charged engineered MspA nanopores.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deciphering the complex chemical code of post-translational modifications (PTMs) is fundamental to proteomics but remains challenging due to the low abundance of modified proteins and the difficulty in resolving isobaric positional isomers. Conventional mass spectrometry and affinity-based methods often lack the sensitivity or specificity required to capture this full chemical diversity. Here, we present a general strategy for site-specific PTM recognition based on MspA nanopores engineered with polar charged residues. By systematically tuning the constriction site (position N91) with polar charged residues, we introduced specific electrostatic, electroosmotic flow and steric interactions that dramatically enhance molecular recognition capabilities. This engineered interface enabled the label-free discrimination of 10 distinct PTM types across 26 peptides, including phosphorylation, glycosylation, and-reported here for the first time
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.